Should You Invest in Mirum Pharmaceuticals (MIRM)?

Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - All asset classes except fixed income outside the U.S. posted positive returns during the quarter [1] - The fund's top five holdings were highlighted as its best picks for 2025 [1] Group 2 - Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) was noted for a one-month return of 15.54% and a 52-week gain of 79.65%, with a market capitalization of $3.905 billion as of January 5, 2026 [2] - Mirum Pharmaceuticals reported revenue of $133 million in Q3 2025, reflecting a nearly 50% year-over-year increase [3] - The company is developing new applications for its flagship treatment, Livmarli, to address a third indication [3]